Investigational product accountability in clinical trials: the complete step-by-step guide for site staff

Under ICH GCP E6(R3), responsibility for investigational product accountability at the trial site rests with the investigator or institution. This means the principal investigator (PI) is the person ultimately accountable for ensuring that the site’s accountability systems and records are complete, accurate, and compliant with the protocol and sponsor’s instructions. For a deeper explanation of how responsibility is distributed between the sponsor and the investigator across the full IP management lifecycle, see our guide: what is an investigational medicinal product? The essential GCP guide.
In practice, the day-to-day execution of investigational product accountability is almost always delegated. The structure of that delegation varies by site type and by the nature of the trial.
The principal investigator
The PI holds overall accountability and must ensure that the delegation is appropriate, that delegated staff are trained before they begin accountability activities, that the delegation is documented on the site’s delegation of authority (DoA) log, and that they review accountability records at regular intervals. The PI cannot delegate accountability itself, only the activities. If a delegated staff member makes an error in the drug accountability log, it is the PI who is responsible to the regulatory authority.
The site pharmacist or pharmacy coordinator
In hospital-based or academic medical center trials, a qualified pharmacist is typically the primary delegatee for investigational product accountability. The pharmacist receives shipments, maintains the physical inventory, prepares and dispenses the investigational product, and maintains the drug accountability log. In blinded studies, the pharmacist is frequently the only person at the site with access to the unblinded treatment assignment, making their role in accountability particularly sensitive.
The clinical research coordinator or IP coordinator
In community-based sites or early-phase studies without dedicated pharmacy support, a trained clinical research coordinator (CRC) or designated IP coordinator may carry out accountability activities. This requires specific training on the sponsor’s accountability procedures, the protocol’s dispensing requirements, and the site’s SOPs for IP handling.
Sub-investigators and other delegated staff
Sub-investigators may be delegated specific accountability tasks such as reviewing and countersigning accountability records. Study nurses or research assistants may be delegated tasks such as receiving returned product from participants and recording the return in the accountability log. All delegations must be documented on the DoA log, and each person must be trained before performing the delegated activity.
A common GCP inspection finding is that accountability activities were performed by staff who were not listed on the DoA log or whose training for those activities was not documented. This is addressed in depth in our guide on the differences between ICH GCP E6 R2 and E6 R3, which outlines the strengthened requirements for role-specific documentation under E6(R3).

Step 1: receiving the investigational product

Investigational product accountability begins the moment the investigational product arrives at the site. The receipt process is the foundation of the accountability record, and errors made at this stage can compromise the entire downstream chain of documentation.

Upon receipt of a shipment, the following steps must be completed:

1. Inspect the outer packaging for damage before opening. Note and photograph any damage.
2. Check the temperature monitoring record, typically a data logger or a time-temperature indicator, included in the shipment. Record the temperature range during transit. If a temperature excursion occurred, quarantine the product immediately and notify the sponsor before using it.
3. Open the shipment and verify the contents against the packing slip. Confirm the product name, batch or lot number, quantity, dosage form and strength, expiry date, and storage conditions match what is listed on the packing slip and what is expected under the protocol.
4. Record all of the above information in the drug accountability log on the day of receipt. Do not defer entry to a later date.
5. Store the investigational product immediately in the designated secure storage area at the conditions specified by the sponsor.
6. Sign and date the receipt entry in the drug accountability log, and ensure the delivery receipt is filed in the site’s essential documents.

Key GCP requirement: ICH GCP E6(R3) requires that records of receipt be made on the day of delivery. Retrospective entries, even if accurate, are a data integrity violation and a common inspection finding. Every receipt must be contemporaneous.

————-

Step 2: storing the investigational product correctly

Once received, the investigational product must be stored under conditions that maintain its integrity until it is dispensed. Storage requirements are established by the sponsor based on stability data and must be communicated to the site in the Investigator’s Brochure (IB), on the product label, and, where applicable, in a dedicated IP pharmacy manual or site instructions.
ICH GCP E6(R3) requires that investigational products be stored in a designated, secure area, accessible only to authorized personnel. For most trials, this means a locked cabinet or refrigerator within a locked pharmacy or dispensary, with access restricted to the staff listed on the delegation of authority log.
The following storage controls must be in place:

• Temperature monitoring must be continuous and documented. Sponsors typically require the use of a calibrated data logger or a continuously recording thermometer. The temperature record must be reviewed and initialed at defined intervals, commonly daily or at each working day.
• The investigational product must be stored separately from other clinical or commercial pharmaceutical products to prevent any mix-up.
• If the investigational product is blinded, the storage arrangement must prevent inadvertent unblinding. In double-blind trials, the investigational product and its matching placebo are often stored together under conditions designed to prevent unauthorized access to the allocation code.
• Controlled substances, including investigational products that fall under controlled substance legislation, must be stored in accordance with the applicable national or state regulations in addition to the sponsor’s requirements.

Temperature excursions, meaning deviations from the permitted storage temperature range, must be reported to the sponsor immediately and managed according to the sponsor’s deviation procedure. For a comprehensive guide to handling temperature deviations and other IP storage issues, review the relevant sections of our investigational medicinal product GCP guide.

————-

Step 3: completing the drug accountability log

The drug accountability log, also called the IP accountability log, the IP dispensing log, or the study drug accountability record, depending on the sponsor’s terminology, is the central document of investigational product accountability at the site. It is a running ledger that records every transaction involving the investigational product: every receipt, every dispensing, every return from a participant, every waste event, and every return to the sponsor or destruction.
The drug accountability log is reviewed by monitors at every monitoring visit, by auditors during GCP audits, and by regulatory inspectors during inspections. A complete, consistent, and contemporaneous drug accountability log is one of the most important markers of site quality.

What every drug accountability log must contain

Although the exact format of the drug accountability log is generally defined by the sponsor and provided to the site, all accountability logs must capture the following minimum information:

• Product name and, where applicable, blinded kit number or randomization code.
• Batch or lot number for each unit received or dispensed.
• Expiry date for each batch.
• Quantity received, with the date of receipt and the source of the shipment.
• Quantity dispensed, with the date of dispensing and the participant’s identification number. Personal identifiers such as name or date of birth must not be used in accountability logs to protect participant privacy and maintain blinding where applicable.
• Quantity returned by the participant, with the date of return.
• Any quantity wasted, with the reason for waste (for example, mixing error, broken vial, spilled dose, expired product) and the name of the person who witnessed the waste.
• Running balance: the quantity of investigational product that should be physically present in storage at any point. This is the mathematical sum of all receipts minus all dispensings, returns to sponsor, waste events, and destructions.
• Name, signature, and date of the person completing each entry.
  

How to complete each entry correctly

Investigational product accountability requires strict application of the ALCOA+ principles of data integrity: Attributable, Legible, Contemporaneous, Original, Accurate, and additionally Complete, Consistent, Enduring, and Available.
In practical terms, this means:

• Each entry must be made at the time of the activity, not reconstructed afterward. If you dispense an investigational product to a participant at 10 am, the entry must be made on that date. Backdating is a serious GCP violation.
• Each entry must be attributable to the person who made it. The entry must bear the handwritten or verified electronic signature of the person who performed the activity, not the person who supervised it.
• Errors must be corrected using a single line strike-through, not by erasing or using correction fluid, with the correct entry, the date, and the initials of the person making the correction written alongside.
• Blank fields must not be left unmarked. If a field is not applicable for a particular entry, it should be marked as ‘N/A’ so it is clear the field was not overlooked.
• The running balance must be updated at every entry. A balance column that is not current is one of the most common accountability errors found during monitoring visits.

Paper versus electronic drug accountability records
Many sponsors now provide sites with electronic drug accountability systems, either integrated into their IRT (Interactive Response Technology) platform or as standalone electronic databases. Under ICH GCP E6(R3) and the FDA’s 21 CFR Part 11 regulations on electronic records, electronic accountability records are fully acceptable as source documents, provided the system is validated, access-controlled, audit-trailed, and backed up.
Whether the drug accountability log is paper-based or electronic, the fundamental requirements are the same: every transaction must be recorded completely, accurately, and at the time it occurs. Sites that use electronic IRT-linked systems must still understand the full scope of the accountability record because monitors will cross-check the electronic data against other source documents, including participant visit records and case report forms (CRFs).

————-

Step 4: dispensing the investigational product to participants

Dispensing is the process of providing the investigational product to a trial participant in accordance with the protocol’s dosing schedule and the sponsor’s dispensing instructions. It is one of the most consequential activities in investigational product accountability because errors at the dispensing stage can directly affect participant safety and data validity.
Before dispensing, the authorized dispenser must verify each of the following:

• The participant is enrolled in the trial and has a valid, current informed consent form on file. Dispensing investigational product to a participant who has not provided valid informed consent is a critical GCP violation.
• The participant is eligible to receive the dose at this visit based on any protocol-specified eligibility criteria that apply at the time of dispensing, such as laboratory values, body weight, or concomitant medication exclusions.
• The investigational product to be dispensed is within its expiry date.
• The batch or lot number and kit number to be dispensed are those assigned by the IRT system, if applicable.
• The quantity to be dispensed matches the dose and supply period specified in the protocol for this participant at this visit.

After dispensing, the dispenser must immediately complete the dispensing entry in the drug accountability log, recording the participant’s identification number, the date, the product dispensed, the batch or lot number, the expiry date, the quantity dispensed, and their own name and signature.

Note on blinded trials: In double-blind trials, the dispenser may not know whether they are dispensing active product or placebo. The accountability log entry is made using the kit number assigned by the IRT system, which encodes the treatment allocation. The log itself does not record the treatment allocation, only the kit identifier. This is essential to maintain the integrity of the blind.

————-

Step 5: managing participant returns and unused product

Most clinical trials require participants to return unused investigational product at each visit. This serves two purposes: it allows the site to verify compliance with the dosing regimen by counting returned units, and it ensures that unused investigational product does not remain in an uncontrolled environment outside the trial.
When a participant returns unused product, the following steps apply:

• Count the returned units in the presence of the participant or a witness.
• Record the returned quantity, the date of return, the participant’s identification number, and the lot number in the drug accountability log immediately.
• Store the returned product separately from fresh stock, in a clearly labeled section of the secure storage area designated for returned product, until the sponsor’s instructions for return or destruction are received.
• Where the protocol requires counting of returned units to assess compliance, calculate the number of units consumed (units dispensed minus units returned) and record this in the drug accountability log and/or the participant’s source record as required by the protocol.

Discrepancies between expected returns and actual returns must be documented and explained. A participant who does not return expected units is not necessarily non-compliant, they may have misunderstood the return requirement, but the discrepancy must be resolved, documented, and reported to the sponsor as specified in the protocol.
Partially used vials, reconstituted products, and open containers require special handling instructions that must be provided by the sponsor. Sites must not destroy or dispose of any investigational product unless they have received explicit written authorization from the sponsor to do so.

————-

Step 6: investigational product reconciliation

Reconciliation is the process of mathematically verifying that the drug accountability log is internally consistent and that the physical inventory of investigational product matches the balance that the log records should show. It is one of the most critical activities in investigational product accountability because it is the mechanism by which discrepancies are identified.
The reconciliation formula is straightforward:

Reconciliation formula: Opening balance + Quantity received = Total available. Total available – Quantity dispensed – Quantity returned to sponsor – Quantity destroyed/wasted = Closing balance. The closing balance must equal the quantity physically present in the secure storage area.

Reconciliation should be performed at defined intervals as specified by the sponsor and at a minimum:

• At each monitoring visit, in conjunction with the monitor.
• At the end of the study or upon site closure.
• Whenever a discrepancy is suspected.
• Whenever a shipment is received or a return is made to the sponsor.

When reconciliation reveals a discrepancy, meaning the calculated balance does not match the physical count, the site must immediately investigate. Common causes include missed entries, transcription errors, unrecorded waste events, and delayed documentation of dispensing activities. If the discrepancy cannot be resolved, it must be reported to the sponsor in writing.
Persistent or unexplained discrepancies in investigational product accountability are considered a potential signal of diversion or fraud and may trigger an escalated investigation by the sponsor, a GCP audit, or a regulatory inspection. Risk-based monitoring approaches under ICH GCP E6(R3) specifically flag IP accountability discrepancies as a high-priority risk signal that should trigger intensified oversight.

————-

Step 7: preparing for a monitoring visit

The drug accountability log is reviewed at every monitoring visit. A well-maintained accountability log is one of the most powerful indicators of site quality and significantly reduces the likelihood of receiving corrective action requests (CARs) or critical findings. For a full overview of how monitoring is conducted under ICH GCP E6(R3), including what monitors are required to verify at each visit, see our guide on risk-based monitoring in clinical trials.

What monitors check during an IP accountability review

During a monitoring visit, the clinical research associate (CRA) assigned to the trial will typically conduct a full investigational product accountability review, which includes:

• Verifying that all shipments listed in the sponsor’s records are reflected in the site’s accountability log with the correct receipt dates, quantities, and lot numbers.
• Cross-checking dispensing entries in the accountability log against participant visit records, CRF data, and any IRT-generated dispensing reports to confirm consistency.
• Verifying the running balance after each transaction and confirming that the calculated balance matches the physical count of investigational product in storage.
• Reviewing return entries to confirm that participant-returned product has been recorded and stored appropriately.
• Reviewing waste entries to confirm that any discarded product has been properly documented with a reason, a witness, and a corrective disposition.
• Checking expiry dates of product in current storage to confirm that no expired product is available for dispensing.
• Reviewing temperature monitoring records to confirm that storage conditions have been within the permitted range throughout the inter-visit period.
• Verifying that any temperature deviations that occurred have been reported to the sponsor and resolved in accordance with the sponsor’s instructions.

Common errors that monitors flag during IP accountability reviews

The following are the most common investigational product accountability deficiencies identified during monitoring visits and GCP inspections. Awareness of these errors enables site teams to self-audit and correct them before a visit.

• Missing entries: a dispensing event occurred but was not recorded in the log, or was recorded on a different date.
• Balance not updated: the running balance column was not calculated at the time of the transaction, making the log internally inconsistent.
• Incorrect quantity recorded: the quantity dispensed or returned was recorded incorrectly, resulting in a balance discrepancy.
• Unsigned entries: entries were made without the signature of the person who performed the activity, or entries were signed by a supervisor rather than the person who dispensed.
• Use of Tipp-Ex or correction fluid to correct errors: this renders the record unacceptable under ALCOA+ principles and is a critical data integrity finding.
• Dispensing outside the protocol: the lot number dispensed differs from the lot number assigned by the IRT, or the quantity dispensed differs from the protocol-specified dose.
• Temperature excursion not documented or not reported to sponsor.
• Expired product in storage, not quarantined or removed from the available supply.